Research programme: cancer gene therapy - TransaveAlternative Names: SLIT™ TR03; TR 03
Latest Information Update: 11 Sep 2005
At a glance
- Originator Transave
- Class Gene therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 11 Sep 2005 This programme is still in active development - (BIO-2005)
- 18 Aug 2004 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)